Qsymia Alternatives & Comparison
How Qsymia (phentermine and topiramate extended-release) compares to Contrave, Wegovy, Zepbound — mechanism, trial weight-loss results, and cost — plus where to compare vetted providers.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Qsymia Alternatives Compared
The other major non-GLP-1 oral combination — a common head-to-head comparison
Bupropion stimulates hypothalamic pro-opiomelanocortin (POMC) neurons, which release alpha-MSH to reduce appetite, but POMC neurons also release beta-endorphin, which feeds back onto mu-opioid receptors on the POMC neurons themselves and shuts them off — limiting the appetite-suppressing effect.
Qsymia wins on efficacy: EQUIP and CONQUER reported about -10.9% and -9.8% mean body-weight loss at 56 weeks on the highest dose, versus about -6.1% for Contrave in COR-I. Contrave wins on access — it costs about $99/mo cash via Currax, has no REMS program, and no contraception requirement. Both are oral second-line options that pre-date the GLP-1 era; neither approaches Wegovy or Zepbound on efficacy. Pick Qsymia for maximum oral weight loss; pick Contrave if cost, pregnancy planning, or craving-driven eating dominate.
Full Contrave vs Qsymia comparison →GLP-1 injection with substantially greater average weight loss in trials
Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake.
Wegovy delivers larger weight loss (-14.9% in STEP-1 vs -10.9% with top-dose Qsymia in EQUIP) and a proven cardiovascular outcome via SELECT, but Qsymia is the only fully-oral option here, costs roughly a quarter as much (~$100-$200/mo vs $499/mo NovoCare Wegovy), and has a pediatric indication. The catch: Qsymia ships only through a REMS that mandates monthly pregnancy testing and contraception, plus dose-related cognitive fog and paresthesias from topiramate.
Full Wegovy vs Qsymia comparison →Dual GIP/GLP-1 injection with the largest average weight loss of any approved option
Zepbound works through tirzepatide's dual GIP/GLP-1 mechanism to reduce appetite through both central brain signals and peripheral metabolic effects.
Zepbound is roughly twice as effective for weight loss (about 20.9% at 72 weeks vs Qsymia's 10.9% at 56 weeks) and carries an OSA indication. Qsymia stays competitive because it is a once-daily oral capsule, costs ~$100-$200/mo on Qsymia Advantage (generic phentermine plus topiramate runs ~$50/mo), and works without injections. Qsymia ships with a REMS program due to topiramate teratogenicity, requires monthly pregnancy testing in people who can become pregnant, and is contraindicated in pregnancy, glaucoma, and hyperthyroidism. Zepbound wins on magnitude; Qsymia wins on access and route.
Full Zepbound vs Qsymia comparison →GLP-1 injection option for patients who want incretin-class treatment instead
Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours.
In the pivotal SCALE Obesity and Prediabetes trial (Pi-Sunyer et al.
Compare compounded Semaglutide providers
Compounded semaglutide runs a median of $195/month across 519 vetted-provider price points (range $59–$1,585). Featured partners below, ranked by our partner-economics ordering.
Compare compounded Tirzepatide providers
Compounded tirzepatide runs a median of $249/month across 473 vetted-provider price points (range $69–$1,400). Featured partners below, ranked by our partner-economics ordering.
Compare every Qsymia provider
See current pricing, verification status, form, and states served across every vetted provider in one place.